TrialAmerican journal of hematology2021

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.

Pramod K Mistry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.